In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Differences of blood coagulation parameters and platelet counts in patients undergoing transcatheter aortic valve implantation with Edwards SAPIEN 3 or Corevalve Evolut R

Session Poster Session 7

Speaker Taiga Katayama

Congress : ESC Congress 2018

  • Topic : valvular, myocardial, pericardial, pulmonary, congenital heart disease
  • Sub-topic : Aortic Valve Stenosis
  • Session type : Poster Session
  • FP Number : P6316

Authors : T Katayama (Tokyo,JP), N Yokoyama (Tokyo,JP), Y Watanabe (Tokyo,JP), S Takahashi (Tokyo,JP), H Kawamura (Tokyo,JP), M Nakashima (Tokyo,JP), K Kawasugi (Tokyo,JP), K Kozuma (Tokyo,JP)


T. Katayama1 , N. Yokoyama1 , Y. Watanabe1 , S. Takahashi1 , H. Kawamura1 , M. Nakashima1 , K. Kawasugi1 , K. Kozuma1 , 1Teikyo University School of Medicine - Tokyo - Japan ,

European Heart Journal ( 2018 ) 39 ( Supplement ), 1320

Background: Thrombocytopenia after transcatheter aortic valve implantation (TAVI) has been recognized. However, cause of thrombocytopenia post TAVI was not clear.

Purpose: The purpose of this study was to investigate the state and change of the blood coagulation and their influence on post TAVI related thrombocytopenia in patients undergoing TAVI with SAPIEN 3 (S3) or Evolut R (ER).

Methods: We enrolled 63 patients (age: 85±5, male:13) undergoing transfemoral TAVI with S3 (n=38) or ER (n=25) valves. Patients with baseline platelet counts less than 100 ×109/L were excluded in this study. Platelet counts were measured before and after TAVI and 1, 2, 3 and 7 days postoperatively. Coagulation parameters as prothrombin activation fragment 1+2 (F1+2) and thrombin-anti-thrombin complex (TAT) were also assessed. Post TAVI related thrombocytopenia was defined as a decline in platelet count of ≥50% at nadir.

Results: Baseline platelet count was not different between S3 (201×109/L; 183–234×109/L range) and ER (196×109/L; 158–219×109/L range).

All blood coagulation parameters significantly increased on immediately after TAVI, while platelet counts started to drop and reached a nadir at day 3. Then platelet count recovered by day 7.

The change in F1+2 and TAT after S3 implantation was significantly greater than it after ER (Fig). These parameters recovered by Day 7. Thrombocytopenia occurred post TAVI in 23.7% with S3 and in 4% with ER (P=0.074). Platelet count at day 7 after S3 implantation was significantly less than it after ER (138×109/L; 117–166×109/L range vs. 166×109/L; 151–219 ×109/L range, p=0.02).

Conclusion: State of coagulation activation after TAVI differed with S3 and ER. This result may be caused by the structural difference in 2 valves. Although Incidence of thrombocytopenia did not differ between 2 valves, recovery of platelet counts after TAVI was low in patients with S3. Thus, careful attention should be paid to high coagulation status for S3.

Figure 1

Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are